PSMAI cut-off value for mortality in men: 680.1 mm2/m2
Por um escritor misterioso
Descrição
ASCO 2023: LuPARP: Phase 1 Trial of 177Lu-PSMA-617 and Olaparib in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)
Computed tomographic images at the the middle third lumbar vertebral
Reduced Acquisition Time per Bed Position for PET/MRI Using 68Ga-RM2 or 68Ga-PSMA-11 in Patients With Prostate Cancer: A Retrospective Analysis
ESMO 2022: Lu-PSMA for Prostate Cancer Treatment
Reduced Acquisition Time per Bed Position for PET/MRI Using 68Ga-RM2 or 68Ga-PSMA-11 in Patients With Prostate Cancer: A Retrospective Analysis
Long-term outcome of 177Lu-PSMA-617 radioligand therapy in heavily pre-treated metastatic castration-resistant prostate cancer patients
Increased mortality risk in multiple-myeloma patients with subsequent malignancies: a population-based study in the Netherlands
Voluntary Medical Male Circumcision (VMMC)
Immediate Mortality and Five-Year Survival of Employed Men with a First Myocardial Infarction
Reduced Acquisition Time per Bed Position for PET/MRI Using 68Ga-RM2 or 68Ga-PSMA-11 in Patients With Prostate Cancer: A Retrospective Analysis
The forest plots, Galbraith plot, sensitivity analysis, and subgroup
Head-to-head comparison of 68Ga-PSMA-11 PET/CT and 68Ga-PSMA-11 PET/MRI in the detection of biochemical recurrence of prostate cancer: summary of head-to-head comparison studies
ASCO 2022: PRINCE: Phase I Trial of 177Lu-PSMA-617 in Combination with Pembrolizumab in Patients with mCRPC
de
por adulto (o preço varia de acordo com o tamanho do grupo)
